share_log

CVS Health | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

CVS Health | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

西維斯健康 | FWP：自由書寫募資說明書
美股sec公告 ·  05/08 04:54
牛牛AI助理已提取核心訊息
CVS Health Corporation has successfully priced a series of Senior Notes on May 7, 2024, with a total value of $5 billion. The offering includes $1 billion of 5.400% Senior Notes due in 2029, $1 billion of 5.550% Senior Notes due in 2031, $1.25 billion of 5.700% Senior Notes due in 2034, $750 million of 6.000% Senior Notes due in 2044, and $1 billion of 6.050% Senior Notes due in 2054. The notes were priced close to their principal amount and will pay semiannual interest starting December 1, 2024. The maturity dates for these notes range from June 1, 2029, to June 1, 2054. CVS Health has included optional redemption provisions for these notes, allowing the company to redeem the notes before their maturity dates under certain conditions. The offering was managed by a consortium of banks, including BOFA Securities, Inc., Barclays Capital Inc., and others. The notes have been rated Baa2 by Moody's and BBB by S&P. This strategic financial move is aimed at diversifying CVS Health's funding sources and extending its debt maturity profile.
CVS Health Corporation has successfully priced a series of Senior Notes on May 7, 2024, with a total value of $5 billion. The offering includes $1 billion of 5.400% Senior Notes due in 2029, $1 billion of 5.550% Senior Notes due in 2031, $1.25 billion of 5.700% Senior Notes due in 2034, $750 million of 6.000% Senior Notes due in 2044, and $1 billion of 6.050% Senior Notes due in 2054. The notes were priced close to their principal amount and will pay semiannual interest starting December 1, 2024. The maturity dates for these notes range from June 1, 2029, to June 1, 2054. CVS Health has included optional redemption provisions for these notes, allowing the company to redeem the notes before their maturity dates under certain conditions. The offering was managed by a consortium of banks, including BOFA Securities, Inc., Barclays Capital Inc., and others. The notes have been rated Baa2 by Moody's and BBB by S&P. This strategic financial move is aimed at diversifying CVS Health's funding sources and extending its debt maturity profile.
CVS Health Corporation已於2024年5月7日成功對一系列優先票據進行了定價，總價值爲50億美元。此次發行包括將於2029年到期的10億美元5.400％的優先票據，2031年到期的10億美元5.550％的優先票據，2034年到期的12.5億美元5.700％的優先票據，2044年到期的7.5億美元6.000％的優先票據，以及2054年到期的10億美元6.050％的優先票據。這些票據的定價接近其本金，並將從2024年12月1日起支付半年利息。這些票據的到期日爲2029年6月1日至2054年6月1日。CVS Health爲這些票據提供了可選的贖回條款，允許公司在某些條件下在到期日之前贖回票據。此次發行由包括美銀證券公司、巴克萊資本公司等在內的銀行財團管理。這些票據被穆迪評爲Baa2，標準普爾將BBB評爲Baa2。這一戰略財務舉措旨在分散CVS Health的資金來源並延長其債務到期日。
CVS Health Corporation已於2024年5月7日成功對一系列優先票據進行了定價，總價值爲50億美元。此次發行包括將於2029年到期的10億美元5.400％的優先票據，2031年到期的10億美元5.550％的優先票據，2034年到期的12.5億美元5.700％的優先票據，2044年到期的7.5億美元6.000％的優先票據，以及2054年到期的10億美元6.050％的優先票據。這些票據的定價接近其本金，並將從2024年12月1日起支付半年利息。這些票據的到期日爲2029年6月1日至2054年6月1日。CVS Health爲這些票據提供了可選的贖回條款，允許公司在某些條件下在到期日之前贖回票據。此次發行由包括美銀證券公司、巴克萊資本公司等在內的銀行財團管理。這些票據被穆迪評爲Baa2，標準普爾將BBB評爲Baa2。這一戰略財務舉措旨在分散CVS Health的資金來源並延長其債務到期日。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。